News

IPLS Welcomes the CHLA

 

 

 

 

November 2020, The International Partnering in Lifescience Society (IPLS)and Canadian Healthcare Licensing Association (CHLA) are delighted to announce that the CHLA will be joining the IPLS

The IPLS is an umbrella organization for Business Development and Licensing (BD&L) groups in France, Germany, Switzerland, Italy, Spain, United Kingdom, Central & Eastern Europe and the Nordics countries.

The IPLS member groups are dedicated to networking, education and best practice in life-science business development. The IPLS has for over 20 years organized international events and other initiatives for the benefit of its members.

“CHLA is a very dynamic and active association in BD&L in the Canadian Pharmaceutical and Healthcare sector said Dr Rachid Benhamza, President of IPLS. “This new cooperation will certainly contribute to an even better development of our future activities, network and relationships. I would like to welcome our colleagues from Canada and their President Manon Decelles, who will join our board as a representative of CHLA”.

“Thank you Rachid and IPLS. It is an honour for us to join such a dynamic group of people and associations” said Mrs. Manon Decelles, President CHLA. As the pharmaceutical market continue to evolve worldwide with international price reference being on all political agendas, it is more important than ever that our members come together and work collaboratively to ensure new drugs are made available to all patients worldwide”

About IPLS:

The IPLS member groups have some 1500 BD&L professionals working in over 30 countries,

The IPLS was established in 2003 and was originally called the European Pharma Licensing Council (EPLC).

In 2020, the EPLC rebranded to the IPLS to better reflect their global aspirations and objectives.

The IPLS is a not-for-profit organisation. For more information visit www.ipls.online

About CHLA:

The Canadian Healthcare Licensing Association is a non-profit organization with the mission to stimulate the building of relationships and the development of strategic alliances among companies engaged in the provision of pharmaceutical products to Canadians. Our members include over 150 representatives from pharmaceutical companies, innovative and generics, as well as other professionals from the industry. CHLA members meet at least twice a year to hear guest speakers give presentations on topics of interest. Emphasis falls on providing opportunities for sharpening practical skills and on facilitating networking with other BD professionals. The CHLA is led by an Executive Committee whose members are drawn from the broadest possible range of CHLA constituents. Members are appointed annually by the Board, from which a minimum of three members are re-appointed to ensure continuity. For more information visit www.chlassoc.com.

News Archive